View Older Stories View More Recent Stories

Jan 7, 2016 07:32AM Arrowhead Research (ARWR) Announces Dosing in ARC-520 Phase 2b MONARCH Study
Jan 7, 2016 07:30AM Arrowhead Begins Dosing the Phase 2b MONARCH Combination Study of ARC-520 in Patients with Chronic Hepatitis B Infection
Dec 14, 2015 04:01PM Arrowhead Reports Fiscal 2015 Year End Results
Dec 14, 2015 01:17PM Arrowhead Research (ARWR) to Join NASDAQ Biotechnology Index (NBI)
Dec 14, 2015 01:16PM Arrowhead Added to NASDAQ Biotechnology Index®
Dec 7, 2015 04:01PM Arrowhead to Webcast Fiscal 2015 Year End Results
Dec 7, 2015 07:32AM Arrowhead Research (ARWR) Presents Encouraging Data from ARC-520 Combo in HBV
Dec 7, 2015 07:30AM Arrowhead’s ARC-520 Leads to Consistent Immune Reactivation in Chimpanzees with Chronic Hepatitis B Infection
Nov 16, 2015 11:00AM Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of Hepatitis B Viral Antigens and DNA
Nov 15, 2015 06:15PM Arrowhead Presents Data Showing Robust Sustained Anti-viral Effects with ARC-520 in Hepatitis B Infected Chimpanzees
Nov 11, 2015 07:30AM Arrowhead to Present at Upcoming Conferences
Oct 20, 2015 10:00AM Arrowhead Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2015
Oct 14, 2015 09:30AM Arrowhead Presents Overview of Its Broad RNAi Delivery Platform and Introduces New Subcutaneously Administered Format
Oct 5, 2015 07:30AM Arrowhead to Present at Upcoming Conferences
Sep 24, 2015 07:30AM Arrowhead Reports Peak Reduction in HBsAg of Up to 99% (1.9 log) After a Single Dose with Hepatitis B Candidate ARC-520 in Treatment Naïve Cohort of Phase 2a Study
Sep 11, 2015 07:30AM Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC™ Delivery System
Sep 10, 2015 07:30AM Arrowhead to Webcast Analyst Day Presentation on Hepatitis B Candidate ARC-520
Aug 5, 2015 12:15PM Streetinsider.com's Hot Lunchtime Reads 8/5: (MSFT) (KERX) (PCLN) (ARWR)
Aug 5, 2015 07:30AM Arrowhead to Present at Jefferies 2015 Hepatitis B Summit
Aug 4, 2015 04:01PM Arrowhead Reports Fiscal 2015 Third Quarter Financial Results
Jul 28, 2015 04:30PM Arrowhead to Report Fiscal 2015 Third Quarter Financial Results
Jul 8, 2015 07:30AM Arrowhead Receives Regulatory Clearance for ARC-AAT Phase 1 in the United Kingdom and New Zealand
Jul 2, 2015 07:30AM Arrowhead Initiates Dosing of ARC-AAT in Patients with Alpha-1 Antitrypsin Deficiency
Jun 17, 2015 07:30AM Arrowhead Receives Regulatory Clearance to Begin Additional Phase 2b Studies of Hepatitis B Candidate ARC-520
Jun 10, 2015 12:27PM Arrowhead Receives Orphan Drug Designation for ARC-AAT
May 27, 2015 07:30AM Arrowhead to Present at Jefferies 2015 Healthcare Conference
May 11, 2015 04:01PM Arrowhead Reports Fiscal 2015 Second Quarter Financial Results
May 6, 2015 03:15PM Arrowhead Presents Data on Potential RNAi Candidate Targeting Factor 12 Mediated Angioedemic and Thromboembolic Diseases
May 5, 2015 07:30AM Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT
May 4, 2015 04:01PM Arrowhead to Report Fiscal 2015 Second Quarter Financial Results
Apr 30, 2015 07:30AM Arrowhead Publishes Data on Advances in Subcutaneous siRNA Delivery
Apr 28, 2015 04:01PM Arrowhead to Present at Upcoming Conferences
Apr 13, 2015 07:30AM Arrowhead Cleared to Proceed with Multiple Dose Phase 2b Study of ARC-520
Mar 5, 2015 07:30AM Arrowhead Acquires Novartis’ RNAi Research and Development Portfolio
View More Recent Stories View Older Stories